Trial Profile
A phase I/IIa trial of autologous tumor-dendritic cell fusion (dendritoma) vaccine combined with low dose interleukin-2 in stage IV melanoma patients
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Oct 2016
Price :
$35
*
At a glance
- Drugs Tumour lysate particle-loaded dendritic cell vaccine Elios Therapeutics (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 17 Oct 2016 New trial record